Nyxoah (NASDAQ:NYXH – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.
Analyst Recommendations
This is a breakdown of recent ratings for Nyxoah and InspireMD, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 1 | 1 | 2 | 0 | 2.25 |
| InspireMD | 0 | 0 | 3 | 0 | 3.00 |
Nyxoah presently has a consensus target price of $3.55, indicating a potential upside of 303.55%. InspireMD has a consensus target price of $4.50, indicating a potential upside of 734.88%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Nyxoah.
Insider & Institutional Ownership
44.8% of InspireMD shares are owned by institutional investors. 25.0% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Nyxoah and InspireMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -443.16% | -178.90% | -81.83% |
| InspireMD | -413.96% | -69.42% | -57.68% |
Risk and Volatility
Nyxoah has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Valuation and Earnings
This table compares Nyxoah and InspireMD”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $11.33 million | 3.01 | -$101.92 million | ($2.52) | -0.35 |
| InspireMD | $10.84 million | 2.31 | -$19.92 million | ($0.64) | -0.84 |
InspireMD has lower revenue, but higher earnings than Nyxoah. InspireMD is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.
Summary
InspireMD beats Nyxoah on 10 of the 14 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
